Skip to main content Skip to home page
 

Monoclonal Antibody Treatment

Deaconess is administering monoclonal antibody medications with emergency use authorization to help prevent hospitalization for COVID-19.   

Currently, we are administering Sotrovimab, Bamlanivimab/Etesevimab and the Regeneron product Casirivimab/Imdevimab. Monoclonal Antibodies Infographic
  These medications are given as an infusion treatment of mild-to-moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization.   
 

Who Qualifies

Adults who are at high risk are defined as being having  at least ONE of the following criteria:

  • BMI ≥ 25
  • Chronic Kidney Disease
  • Diabetes
  • Immunosuppressive disease
  • Currently receiving immunosuppressive treatment
  • Age ≥ 65
  • Age ≥ 55 AND have at least one of the following
    • Cardiovascular disease
    • Hypertension
    • COPD/chronic respiratory disease

Adult patients who are vaccinated, have at least one of the risk factors above, and/or are experiencing severe "breakthrough" symptoms, may also be eligible for this treatment.  


Adolescents who are at high risk are defined as having at least ONE of the following criteria:

  • BMI ≥ 85th percentile
  • Sickle cell disease
  • Congenital or acquired heart disease
  • Neurodevelopmental disorders, such as Cerebral palsy
  • Medical related technological dependence (ie tracheostomy, gastrostomy)
  • Asthma or other chronic respiratory disease requiring daily maintenance medications
Adolescent patients who are vaccinated, have at least one of the risk factors above, and/or are experiencing severe "breakthrough" symptoms, may also be eligible for this treatment.  

Monoclonal antibody infusion is NOT authorized for:
  • Hospitalized patients due to COVID-19
  • Patients on oxygen due to COVID-19 OR patients with SpO2 ≤ 93%
  • Patients on chronic oxygen therapy that are requiring increased levels of oxygen due to COVID-19
  • Patients with COVID-19 symptom onset ≥ 10 days
    • Clinical trial data shows most benefit in patients with symptoms of 7 days or less
    • Treatment should be started as early as possible
If you believe you are a candidate for monoclonal antibody treatment, schedule an appointment now with a Deaconess Clinic LIVE provider.  They will assess your symptoms and/or risks, and will schedule any needed appointments for treatment. 

*Maryland Department of Health. What are Monoclonal Antibodies Infographic, Retrieved 2021, Aug 20, from https://health.maryland.gov/preparedness/Pages/Monoclonal-Antibodies-Treatment-for-COVID-19.aspx
Top Back to top